Unfractionated heparin vs low molecular weight heparin in acute coronary syndromes;Heparina no fraccionada vs heparina de bajo peso molecular en síndromes coronaries agudos

Archivos de Cardiologia de Mexico

Volumn 71, Issue SUPPL. 1, 2001, Pages

  Pacheco, H G ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Acute coronary syndrome; Low molecular weight heparin; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

ACUTE HEART INFARCTION; ANTICOAGULATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; DRUG EFFICACY; DRUG USE; HEART MUSCLE ISCHEMIA; HEPARINIZATION; HUMAN; META ANALYSIS; REVIEW; RISK BENEFIT ANALYSIS;

ACUTE DISEASE; CORONARY DISEASE; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; SYNDROME;

EID: 0035020476     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Acute coronary syndromes: Unstable angina and non Q-wave myocardial infarction
2. Low-molecular-weight heparin during instability in coronary artery disease
3. New antithrombotic agents
4. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina
5. Antiplatelet and anticoagulant use after myocardial infarction
6. Low-molecular-weight heparins
7. Are the available low-molecular-weight heparin preparations the same?
8. Low-molecular-weight heparin during instability in coronary artery disease
9. For the Fric Investigators: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for six week in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC)
10. Comparison of two treatment duration (6 days and 14 days) of a low molecular weight heparin with a 6 day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (FRAxiparine -in Ischaemin Syndrome)
11. For the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
12. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
13. For the TIMI-11B and Essence Investigators: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction: TIMI-11B-ESSENCE meta-analysis
14. Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin?